Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Rychli, K; Richter, B; Hohensinner, PJ; Kariem Mahdy, A; Neuhold, S; Zorn, G; Berger, R; Mörtl, D; Huber, K; Pacher, R; Wojta, J; Niessner, A; Hülsmann, M.
Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure.
Heart. 2011; 97(14):1158-1163
Doi: 10.1136/hrt.2010.220228
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mahdy Ali Kariem
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective To assess the prognostic value of the mitogenic, antiapoptotic, angiogenic and antifibrotic hepatocyte growth factor (HGF) in heart failure (HF). Design Prospective cohort study. Setting/patients Assessment of HGF levels at inclusion in 351 patients with advanced HF (median 75 years, interquartile range (IQR) 63-82, 66% male). Main outcome measures All-cause mortality, cardiovascular mortality. Results During a median follow-up of 16 months, 26% of patients died. HGF tertiles were associated with an increasing risk for all-cause mortality (p<0.001) with a hazard ratio (HR) of 3.06 (95% confidence interval (CI) 1.69 to 5.53) for the third compared with the first tertile. This association remained significant after multivariable adjustment for B-type natriuretic peptide (BNP) and other risk factors (p=0.002). Subgroup analysis revealed that HGF was a strong predictor of the secondary end point cardiovascular mortality in ischaemic HF (p=0.009) with an adjusted HR of 6.2 (95% CI 1.76 to 21.8) comparing the third with the first tertile but not in non-ischaemic HF (HR=1.47, 95% CI 0.48 to 4.49, p=0.5). Patients with high HGF but low BNP had a comparable survival rate to those with elevated BNP but low HGF (p=0.66). Of note, the dose of angiotensin converting enzyme (ACE) inhibitors inversely correlated with HGF concentrations (r=-0.25, p<0.001). Conclusions HGF is a strong and independent predictor of mortality in advanced HF and, in particular, in ischaemic HF. These results indicate that HGF with its multiple effects on myocardial function exerts an overall deleterious effect in advanced HF. HGF may be of special interest for risk prediction and tailoring of HF treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Aged, 80 and over -
- Biological Markers - blood
- Chi-Square Distribution -
- Enzyme-Linked Immunosorbent Assay -
- Female -
- Heart Failure - blood Heart Failure - diagnosis Heart Failure - etiology Heart Failure - mortality
- Hepatocyte Growth Factor - blood
- Humans -
- Kaplan-Meier Estimate -
- Linear Models -
- Male -
- Middle Aged -
- Myocardial Ischemia - complications Myocardial Ischemia - mortality
- Natriuretic Peptide, Brain - blood
- Predictive Value of Tests -
- Prognosis -
- Proportional Hazards Models -
- Risk Assessment -
- Risk Factors -
- Up-Regulation -